BioUtah COVID-19 Analysis
-
PPP2 Loans Are Now Open
PPP loans have been reopened with an infusion of $284 billion for First Draw and Second Draw loans.…
-
Sanofi Commits $1M to Support Parkinson’s Disease Genetic Research
Sanofi and the Parkinson’s Foundation announced on Wednesday a new research collaboration to advance the availability of genetic…
-
J&J Enters Phase 3 Trial for COVID-19 Vaccine
BioUtah member Johnson & Johnson (J&J) announced that they’ve started the global phase 3 trial of Janssen’s single-dose…
-
Fulgent Genetics Lands Utah COVID-19 Testing Contract
TestUtah has some new twists. Following the expiration of certain state contracts September 1, the Utah Department of…
-
Efficacy of Face Masks, Respirators and Face Coverings
Article written by Janelle Bentz, Nelson Labs What is the difference between a medical face mask and respirator,…
-
BioUtah’s Summary of Governor’s Economic Response Plan
On Tuesday afternoon, March 24, 2020, Governor Herbert unveiled an economic response plan to the coronavirus CoronaVirus for…
-
BioUtah Statement & Recommendations to Members on COVID-19
The advent and progression of the Novel Coronavirus, COVID-19, pandemic requires a proper and measured response from every…
Call to Action
Post Category
- BioUtah COVID-19 Analysis
- BioUtah News
- Business Tools & Resources
- Call to Action
- chair
- COVID-19 Legislation
- COVID-19 Updates
- Economic Developments
- Events
- Events
- Feature
- Featured Members
- Federal News
- Funding
- Funding
- Guests Posts
- HHS/FDA & Other Regulatory
- HR
- Industry News
- Life Sciences Events
- Life Sciences Industry News
- Newsletters
- Non-chair
- Policy News
- Press Releases
- State News
- Utah's Life Sciences Companies
- Workplace Safety
Latest Posts
- Lumea Named Best New Biopsy Technology Solution in 2026 MedTech Breakthrough Awards
- Co-Diagnostics Develops Ebola Assay Strategy Following Recent Global Outbreak Alert
- BlueWind Medical Secures $47.8 Million Financing to Accelerate Commercialization of Revi® System
- PhotoPharmics Announces Last Patient Last Visit in Pivotal, Phase 3, Light for PD Clinical Trial; Company to Present Topline Data at World Parkinson Congress
- AFTER SUCCESSFUL FDA MEETING, CLENE FILING ACCELERATED APPROVAL NDA FOR ALS
